The Prevalence and Cost of Unapproved Uses of Top-Selling Orphan Drugs

• Aaron S. Kesselheim ,

  * E-mail: akesselheim@partners.org

  Affiliation Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Jessica A. Myers,

  Affiliation Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Daniel H. Solomon,

  Affiliations Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America, Division of Rheumatology, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Wolfgang C. Winkelmayer,

  Affiliation Division of Nephrology, Stanford University School of Medicine, Palo Alto, California, United States of America

  ⨯
• Raisa Levin,

  Affiliation Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯
• Jerry Avorn

  Affiliation Division of Pharmacoepidemiology and Pharmacoeconomics, Department of Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, United States of America

  ⨯